Drug Interactions between Fumatinic and praziquantel
This report displays the potential drug interactions for the following 2 drugs:
- Fumatinic (multivitamin with iron)
- praziquantel
Interactions between your drugs
No interactions were found between Fumatinic and praziquantel. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Fumatinic
A total of 100 drugs are known to interact with Fumatinic.
- Fumatinic is in the following drug classes: iron products, vitamin and mineral combinations.
- Fumatinic is used to treat the following conditions:
praziquantel
A total of 111 drugs are known to interact with praziquantel.
- Praziquantel is in the drug class anthelmintics.
-
Praziquantel is used to treat the following conditions:
- Beef Tapeworm Infection
- Cysticercus cellulosae
- Dog Tapeworm Infection
- Dwarf Tapeworm Infection
- Echinococcus
- Fasciolopsis buski, Intestinal Fluke
- Fish Tapeworm Infection
- Heterophyes heterophyes, Intestinal Fluke
- Liver Fluke
- Metagonimus yokogawai, Intestinal Fluke
- Naophyetus salmincola
- Opisthorchis viverrini, Liver Fluke
- Paragonimus westermani, Lung Fluke
- Pork Tapeworm Infection
- Schistosoma haematobium
- Schistosoma japonicum
- Schistosoma mansoni
- Schistosoma mekongi
Drug and food interactions
praziquantel food
Applies to: praziquantel
ADJUST DOSING INTERVAL: Administration with food increases the oral bioavailability of praziquantel. The mechanism has not been described. In nine healthy volunteers, administration of praziquantel (1800 mg single oral dose) following a high-fat meal increased the mean praziquantel peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 243% and 180%, respectively, compared to administration under fasting conditions. Administration with a high-carbohydrate meal increased these values by 515% and 271%, respectively, compared to fasting. Overall, the relative bioavailability was increased by a factor of 2.72 and 3.98 with the high-fat and high-carbohydrate meals, respectively. The time to reach peak concentration (Tmax) and elimination half-life (T1/2) were not significantly altered.
Coadministration with grapefruit juice may increase the oral bioavailability of praziquantel. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruit. In 18 healthy volunteers, administration of praziquantel (1800 mg single oral dose) with 250 mL of commercially squeezed grapefruit juice resulted in increases in the mean praziquantel Cmax and AUC of 63% and 90%, respectively, compared to administration with water. The Tmax and T1/2 were not significantly altered. The pharmacokinetics of praziquantel were subject to a high degree of interpatient variability with and without grapefruit juice.
MANAGEMENT: To ensure maximal oral absorption, praziquantel should be administered with meals. Administration with grapefruit juice may further increase pharmacologic effects of praziquantel, including adverse effects such dizziness, abdominal discomfort, and nausea.
References (2)
- Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J (2002) "Interaction between grapefruit juice and praziquantel in humans." Antimicrob Agents Chemother, 46, p. 1614-6
- Castro N, Medina R, Sotelo J, Jung H (2000) "Bioavailability of praziquantel increases with concomitant administration of food." Antimicrob Agents Chemother, 44, p. 2903-4
multivitamin with iron food
Applies to: Fumatinic (multivitamin with iron)
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References (2)
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.